Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis

Morie A. Gertz, Morton Scheinberg, Márcia Waddington-Cruz, Stephen Heitner, Chafic Karam, Brian Drachman, Sami Khella, Carol Whelan, Laura Obici

Research output: Contribution to journalArticle

Abstract

Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is an underdiagnosed, progressive, and fatal multisystemic disease with a heterogenous clinical phenotype that is caused by TTR gene mutations that destabilize the TTR protein, resulting in its misfolding, aggregation, and deposition in tissues throughout the body. Areas covered: Inotersen, an antisense oligonucleotide inhibitor, was recently approved in the United States and Europe for the treatment of the polyneuropathy of ATTRv based on the positive results obtained in the pivotal phase 3 trial, NEURO-TTR. This review will discuss the mechanism of action of inotersen and its pharmacology, clinical efficacy, and safety and tolerability. A PubMed search using the terms ‘inotersen,’ ‘AG10,’ ‘antisense oligonucleotide,’ ‘hereditary transthyretin amyloidosis,’ ‘familial amyloid polyneuropathy,’ and ‘familial amyloid cardiomyopathy’ was performed, and the results were screened for the most relevant English language publications. The bibliographies of all retrieved articles were manually searched to identify additional studies of relevance. Expert opinion: Inotersen targets the disease-forming protein, TTR, and has been shown to improve quality of life and neuropathy progression in patients with stage 1 or 2 ATTRv with polyneuropathy. Inotersen is well tolerated, with a manageable safety profile through regular monitoring for the development of glomerulonephritis or thrombocytopenia.

Original languageEnglish (US)
Pages (from-to)701-711
Number of pages11
JournalExpert Review of Clinical Pharmacology
Volume12
Issue number8
DOIs
StatePublished - Aug 3 2019

Fingerprint

Polyneuropathies
Antisense Oligonucleotides
Familial Amyloid Neuropathies
Familial Amyloidosis
Safety
Expert Testimony
Bibliography
Glomerulonephritis
Cardiomyopathies
Amyloid
PubMed
Thrombocytopenia
Publications
Proteins
Language
Quality of Life
Pharmacology
Phenotype
Mutation
Therapeutics

Keywords

  • cardiomyopathy
  • Hereditary transthyretin-mediated amyloidosis
  • inotersen
  • peripheral neuropathy
  • ribonucleic acid interference
  • transthyretin

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. / Gertz, Morie A.; Scheinberg, Morton; Waddington-Cruz, Márcia; Heitner, Stephen; Karam, Chafic; Drachman, Brian; Khella, Sami; Whelan, Carol; Obici, Laura.

In: Expert Review of Clinical Pharmacology, Vol. 12, No. 8, 03.08.2019, p. 701-711.

Research output: Contribution to journalArticle

Gertz, Morie A. ; Scheinberg, Morton ; Waddington-Cruz, Márcia ; Heitner, Stephen ; Karam, Chafic ; Drachman, Brian ; Khella, Sami ; Whelan, Carol ; Obici, Laura. / Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. In: Expert Review of Clinical Pharmacology. 2019 ; Vol. 12, No. 8. pp. 701-711.
@article{4facda7b672d496bb9be1e968a48440b,
title = "Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis",
abstract = "Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is an underdiagnosed, progressive, and fatal multisystemic disease with a heterogenous clinical phenotype that is caused by TTR gene mutations that destabilize the TTR protein, resulting in its misfolding, aggregation, and deposition in tissues throughout the body. Areas covered: Inotersen, an antisense oligonucleotide inhibitor, was recently approved in the United States and Europe for the treatment of the polyneuropathy of ATTRv based on the positive results obtained in the pivotal phase 3 trial, NEURO-TTR. This review will discuss the mechanism of action of inotersen and its pharmacology, clinical efficacy, and safety and tolerability. A PubMed search using the terms ‘inotersen,’ ‘AG10,’ ‘antisense oligonucleotide,’ ‘hereditary transthyretin amyloidosis,’ ‘familial amyloid polyneuropathy,’ and ‘familial amyloid cardiomyopathy’ was performed, and the results were screened for the most relevant English language publications. The bibliographies of all retrieved articles were manually searched to identify additional studies of relevance. Expert opinion: Inotersen targets the disease-forming protein, TTR, and has been shown to improve quality of life and neuropathy progression in patients with stage 1 or 2 ATTRv with polyneuropathy. Inotersen is well tolerated, with a manageable safety profile through regular monitoring for the development of glomerulonephritis or thrombocytopenia.",
keywords = "cardiomyopathy, Hereditary transthyretin-mediated amyloidosis, inotersen, peripheral neuropathy, ribonucleic acid interference, transthyretin",
author = "Gertz, {Morie A.} and Morton Scheinberg and M{\'a}rcia Waddington-Cruz and Stephen Heitner and Chafic Karam and Brian Drachman and Sami Khella and Carol Whelan and Laura Obici",
year = "2019",
month = "8",
day = "3",
doi = "10.1080/17512433.2019.1635008",
language = "English (US)",
volume = "12",
pages = "701--711",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis

AU - Gertz, Morie A.

AU - Scheinberg, Morton

AU - Waddington-Cruz, Márcia

AU - Heitner, Stephen

AU - Karam, Chafic

AU - Drachman, Brian

AU - Khella, Sami

AU - Whelan, Carol

AU - Obici, Laura

PY - 2019/8/3

Y1 - 2019/8/3

N2 - Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is an underdiagnosed, progressive, and fatal multisystemic disease with a heterogenous clinical phenotype that is caused by TTR gene mutations that destabilize the TTR protein, resulting in its misfolding, aggregation, and deposition in tissues throughout the body. Areas covered: Inotersen, an antisense oligonucleotide inhibitor, was recently approved in the United States and Europe for the treatment of the polyneuropathy of ATTRv based on the positive results obtained in the pivotal phase 3 trial, NEURO-TTR. This review will discuss the mechanism of action of inotersen and its pharmacology, clinical efficacy, and safety and tolerability. A PubMed search using the terms ‘inotersen,’ ‘AG10,’ ‘antisense oligonucleotide,’ ‘hereditary transthyretin amyloidosis,’ ‘familial amyloid polyneuropathy,’ and ‘familial amyloid cardiomyopathy’ was performed, and the results were screened for the most relevant English language publications. The bibliographies of all retrieved articles were manually searched to identify additional studies of relevance. Expert opinion: Inotersen targets the disease-forming protein, TTR, and has been shown to improve quality of life and neuropathy progression in patients with stage 1 or 2 ATTRv with polyneuropathy. Inotersen is well tolerated, with a manageable safety profile through regular monitoring for the development of glomerulonephritis or thrombocytopenia.

AB - Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is an underdiagnosed, progressive, and fatal multisystemic disease with a heterogenous clinical phenotype that is caused by TTR gene mutations that destabilize the TTR protein, resulting in its misfolding, aggregation, and deposition in tissues throughout the body. Areas covered: Inotersen, an antisense oligonucleotide inhibitor, was recently approved in the United States and Europe for the treatment of the polyneuropathy of ATTRv based on the positive results obtained in the pivotal phase 3 trial, NEURO-TTR. This review will discuss the mechanism of action of inotersen and its pharmacology, clinical efficacy, and safety and tolerability. A PubMed search using the terms ‘inotersen,’ ‘AG10,’ ‘antisense oligonucleotide,’ ‘hereditary transthyretin amyloidosis,’ ‘familial amyloid polyneuropathy,’ and ‘familial amyloid cardiomyopathy’ was performed, and the results were screened for the most relevant English language publications. The bibliographies of all retrieved articles were manually searched to identify additional studies of relevance. Expert opinion: Inotersen targets the disease-forming protein, TTR, and has been shown to improve quality of life and neuropathy progression in patients with stage 1 or 2 ATTRv with polyneuropathy. Inotersen is well tolerated, with a manageable safety profile through regular monitoring for the development of glomerulonephritis or thrombocytopenia.

KW - cardiomyopathy

KW - Hereditary transthyretin-mediated amyloidosis

KW - inotersen

KW - peripheral neuropathy

KW - ribonucleic acid interference

KW - transthyretin

UR - http://www.scopus.com/inward/record.url?scp=85068527064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068527064&partnerID=8YFLogxK

U2 - 10.1080/17512433.2019.1635008

DO - 10.1080/17512433.2019.1635008

M3 - Article

VL - 12

SP - 701

EP - 711

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 8

ER -